RADIODIAGNOSIS & RADIOTHERAPY OF LUNG CANCER METASTASES

肺癌在美国每年夺去大约15万人的生命 并且其发病率在全球范围内不断增加。这种疾病的早期诊断是 很难获得。肺癌患者的五年生存率 大约是百分之十四，在过去的几十年里没有改变。 拟议研究的目的是确定 用放射性标记的胸苷类似物5-碘-2'-脱氧尿苷（IUdR） γ-放射性同位素碘-123（I-123），用于放射性同位素检测 肺癌和放射性标记的俄歇电子发射同位素 碘-125或β-发射同位素碘-131用于治疗肺 癌为此，设计了实验来检查特定的 放射性标记的IUdR在荷瘤裸鼠体内的摄取 肺所述的方法应提供机会， 选择性靶向肺内分裂的癌细胞， 肺癌的放射学检测方法以及 有效/辅助治疗方法。

Lung cancer claims approximately 150,000 lives each year in the USA and its incidence is increasing globally. Early diagnosis of this disease is difficult to obtain. The five-year survival rate of patients with lung cancer is approximately 14 percent and has not changed over the past several decades. The purpose of the proposed research is to establish the potential of the thymidine analog 5-iodo-2'-deoxyuridine (IUdR) radiolabeled with the gamma-emitting isotope iodine-123 (I-123) for the scintigraphic detection of lung cancer and radiolabeled with either the Auger electron-emitting isotope iodine-125 or the beta-emitting isotope iodine-131 for the therapy of lung cancer. To this end, experiments have been designed to examine the specific uptake of radiolabeled IUdR in nude mice bearing cancer cells growing within the lungs. The approaches described should provide an opportunity for the selective targeting of dividing cancerous cells within the lungs and lead to methods for scintigraphic detection of lung cancer as well as development of an effective/adjuvant therapeutic approach.